Sarepta And Roche Press Ahead With Elevidys Filing Despite Duchenne Trial Miss
The Phase III EMBARK study has fallen short on its primary endpoint – but Sarepta believes the trial has otherwise produced robust data, and believes a full US approval is justified.
You may also be interested in...
Neuroscience is increasingly a focus for the Swiss pharma giant, and it believes it can stay ahead in multiple sclerosis with fenebrutinib, while making up lost ground in with two key candidates in Alzheimer’s disease.
Strong demand from physicians and families of boys with Duchenne has seen a rapid take-off in sales of the $3.2m gene therapy – but the FDA will have the final say on the product's future after a failed Phase III study.
Pfizer reminded investors it still has a gene therapy in Phase III development for Duchenne muscular dystrophy after Sarepta’s disappointing Phase III readout.